CHEK2 Recombinant Monoclonal Antibody

Code: CSB-RA828105A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, WB, IHC, IF, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

O96017

Target Names

CHEK2

Alternative Names

Serine/threonine-protein kinase Chk2 (EC 2.7.11.1) (CHK2 checkpoint homolog) (Cds1 homolog) (Hucds1) (hCds1) (Checkpoint kinase 2), CHEK2, CDS1 CHK2 RAD53

Species Reactivity

Human

Immunogen

A synthesized peptide from human CHEK2 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

11F12

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Western Blotting(WB) Protocol Immunohistochemistry (IHC) Protocol Immunofluorescence (IF) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Western Blot
Positive WB detected in: Jurakt whole cell lysate(30µg), HT-29 whole cell lysate(30µg), K562 whole cell lysate(30µg), Hela whole cell lysate(30µg), A431 whole cell lysate(30µg), MCF-7 whole cell lysate(30µg)
All lanes: Chk2 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/40000 dilution
Predicted band size: 61 kDa
Observed band size: 66 kDa
Exposure time：40s
IHC image of CSB-RA828105A0HU diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
Immunofluorescence staining of Hela cell with CSB-RA828105A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
Overlay Peak curve showing Hela cells stained with CSB-RA828105A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

CHEK2, also known as checkpoint kinase 2, serves as a critical serine/threonine kinase in the DNA damage response pathway. When double-strand breaks occur, CHEK2 becomes activated through ATM-mediated phosphorylation, subsequently phosphorylating key downstream targets including p53, BRCA1, and CDC25 phosphatases. This positions CHEK2 at the center of cell cycle checkpoint control, making it an essential target for researchers investigating genomic stability, tumor suppression mechanisms, and cancer biology.

This recombinant monoclonal antibody, clone 11F12, offers the reproducibility that demanding experimental workflows require. Because the antibody sequence is defined and production occurs through recombinant expression in rabbit host cells, you can expect consistent performance across different lots—eliminating the variability concerns that can complicate long-term studies or multi-site collaborations.

Validation across multiple platforms demonstrates genuine experimental flexibility. Western blot analysis confirms detection in diverse human cell lines including Jurkat, HT-29, K562, HeLa, A431, and MCF-7, with an observed band at approximately 66 kDa. The slight shift from the predicted 61 kDa molecular weight likely reflects post-translational modifications such as phosphorylation, which is particularly relevant given CHEK2's role as both a kinase and phosphorylation target during checkpoint activation. Immunohistochemistry validation in human placenta tissue and immunofluorescence staining in HeLa cells extend utility to spatial localization studies. Flow cytometry performance has also been confirmed in HeLa cells, supporting quantitative single-cell analyses.

Whether you're examining checkpoint responses to genotoxic stress, characterizing CHEK2 variants associated with hereditary cancer syndromes, or screening therapeutic compounds targeting DNA damage pathways, this antibody provides a reliable foundation for your investigations.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells. Promotes the CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 inhibition.

Gene References into Functions

present study aimed to molecularly define and determine the contribution of two rare, apparently novel CHEK2 Large Genomic Rearrangements, among Greek breast cancer patients. PMID:29785007
CHEK2 Y390C mutation induced the drug resistance of triple negative breast cancer cells to chemotherapeutic drugs. PMID:29761796
CHEK2 Germ Line Mutation is not associated with Familial and Sporadic Breast Cancer. PMID:29479983
Chk1 and Chk2 are significantly expressed in human sperm. In case of sperm DNA damage, up-regulated Chk1 expression may enhance sperm apoptosis and lead to asthenospermia, while increased Chk2 expression may inhibit spermatogenesis and result in oligospermia. PMID:29658237
CHK1 and CHK2 and their activated forms are frequently expressed in HGSC effusions, with higher expression following exposure to chemotherapy, and their expression is related to survival. PMID:29804637
first article to report that identical germline mutation of CHEK2 gene, p.R180C, exists in both NF1 and NF2 patients. PMID:29879026
Results suggested that there was a correlation between mutation of the CHEK2 gene and gastric cancer. PMID:29067458
Truncating variants in PALB2, ATM and CHEK2 , but not XRCC2 were associated with increased breast cancer risk. PMID:28779002
our results identify a novel link between XRRA1 and the ATM/CHK1/2 pathway and suggest that XRRA1 is involved in a DNA damage response that drives radio- and chemoresistance by regulating the ATM/CHK1/2 pathway. PMID:29082250
BRCA2 and CHEK2 play an important role in the genetic susceptibility to urinary tract cancers. PMID:27632928
Checkpoint kinase 2 (Chk2) inhibition suppressed C-terminal acetylation of p53 and delayed the induction of p53-target genes under heat stress (HS). Chk2 inhibition failed to inhibit apoptosis induced by HS, indicating that Chk2 was dispensable for p53-dependent apoptosis under HS. Chk2 inhibition abrogated G2/M arrest and promoted cell death induced by HS in cells with p53 defects. PMID:28733865
The inhibition CHK2 expression reduced detachment-induced apoptosis but did not influence the ability of cells to migrate and invade, which illustrates that CHK2 could inhibit tumor progression and metastatic potential by enhancing anoikis. PMID:29486482
These data suggest that the CHEK2 c.1100delC mutation is associated with an increased risk for MBC in the Finnish population. PMID:28874143
Data suggest that mediator complex subunit 1 (Med1/TRAP220) is a target for checkpoint kinase 2 (Chk2)-mediated phosphorylation and may play a role in cellular DNA damage responses by mediating proper induction of gene transcription upon DNA damage. PMID:28430840
this report conceives a novel strategy of Twist1 suppression through Chk2 induction, which prevents metastatic dissemination and promotes premature senescence in p53-defective invasive cancer cells. PMID:28498365
we have provided evidence in this study that hepatocarcinogenesis with lagging chromosomes elicits the expression of DNA damage response protein Chk2. Thus, the overexpression of Chk2 and its mislocalisation within structures of the mitotic spindle contribute to sustain cell division and chromosomes missegregation. PMID:28360097
PI3K kinase activity is necessary for maintaining 4E-BP1 stability. Our results also suggest 4E-BP1 a novel biological role of regulating cell cycle G2 checkpoint in responding to IR stress in association with controlling CHK2 phosphorylation PMID:28539821
Data show that the checkpoint kinase 1/2 (Chk1/Chk2) inhibitor prexasertib (LY2606368) inhibits cell viability in B-/T-ALL cell lines. PMID:27438145
Results confirm the predicted multiplicative relationship between CHEK2*1100delC and the common low-penetrance susceptibility variants for breast cancer. PMID:27711073
Results show that Chk2 expression is regulated by 14-3-3s in G2-M arrest for non-homologous end joining repair probably via PARP1. PMID:28087741
Results indicate that CHEK2 possesses non-cell-autonomous tumor suppressor functions, and present the Chk2 protein as an important mediator in the functional interplay between breast carcinomas and their stromal fibroblasts through repressing the expression/secretion of SDF-1 and IL-6. PMID:27484185
variants in CHEK2 were associated with moderate risks of breast cancer. PMID:28418444
In this paper, we describe an extension to the BOADICEA model to incorporate the effects of intermediate risk variants for breast cancer, specifically loss of function mutations in the three genes for which the evidence for association is clearest and the risk estimates most precise: PALB2, CHEK2 and ATM PMID:27464310
SIAH2 regulates CHK2 basal turnover, with important consequences on cell-cycle control and on the ability of hypoxia to alter the DNA damage-response pathway in cancer cells. PMID:26751770
CHECK2 rare variants were associated with an increased risk of breast cancer and prostate cancer. PMID:27595995
MCM2-MCM6 complex is required for CHK2 chromatin loading and its phosphorylation to DNA damage response in squamous cell carcinoma cells. PMID:27964702
On the basis of analyses of approximately 87,000 controls and patients with breast cancer from population- and hospital-based studies, our best estimate for the relative risk of invasive breast cancer for carriers of the 1100delC mutation in CHEK2, compared with noncarriers, was 2.26 (95% CI, 1.90 to 2.69). PMID:27269948
the G2 damage checkpoint prevents stable recruitment of the chromosome-packaging-machinery components condensin complex I and II onto the chromatin even in the presence of an active Cdk1. PMID:27792460
data suggest that cancer risks reported for founder mutations may be generalizable to all CHEK2 + s, particularly for breast cancer PMID:27751358
K373E mutation of CHK2 in tumorigenesis PMID:27716909
Checkpoint kinase 1 and 2 signaling is important for apoptin regulation. PMID:27512067
High CHEK2 expression is associated with Lung Adenocarcinoma. PMID:28373435
High expression of pCHK2-Thr68 was associated with decreased patient survival (p = 0.001), but was not an independent prognostic factor. Our results suggest that pCHK2-Thr68 and pCDC25C-Ser216 play important roles in breast cancer and may be potential treatment targets PMID:27801830
Our study reports the first case of Li-Fraumeni syndrome-like in Chinese patients and demonstrates the important contribution of de novo mutations in this type of rare disease. PMID:27442652
hese findings confirmed that 53BP1 loss might be a negative factor for chemotherapy efficacy, promoting cell proliferation and inhibiting apoptosis by suppressing ATM-CHK2-P53 signaling, and finally inducing 5-FU resistance. PMID:27838786
All 14 exons of CHEK2 were amplified and sequenced. PMID:27510020
All 14 exons of CHEK2 were amplified. PMID:27039729
CHEK2 mutation is associated with Pancreatic Cancer. PMID:26483394
Data suggest that nitroxoline induces anticancer activity through AMP-activated kinase (AMPK)/mTOR serine-threonine kinase (mTOR) signaling pathway via checkpoint kinase 2 (Chk2) activation. PMID:26447757
CHEK2 mutation carriers were characterized by older age, a history of gastric cancer in the family, locally advanced disease, lower histologic grade and luminal B type breast cancer. PMID:26991782
The germline mutations of the CHEK2 gene are associated with an increased risk of polycythaemia vera. PMID:26084796
loss of CHK2 or PP6C-SAPS3 promotes Aurora-A activity associated with BRCA1 in mitosis PMID:26831064
we observed a great degree of heterogeneity amongst the CHEK2*1100delC breast cancers, comparable to the BRCAX breast cancers. copy number aberrations were mostly seen at low frequencies in both the CHEK2*1100delC and BRCAX group of breast cancers. PMID:26553136
The aim of this study was to determine the frequency and spectrum of germline mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these patients. PMID:26577449
germ-line CHEK2 mutations affecting protein coding sequence confer a moderately-increased risk of NHL, they are associated with an unfavorable NHL prognosis, and they may represent a valuable predictive biomarker for patients with DLBCL. PMID:26506619
Mutations in CHEK2 were most frequent in patients with hereditary non-triple-negative breast cancers. PMID:26083025
Authors propose that CHK2 is a negative regulator of androgen sensitivity and prostate cancer growth, and that CHK2 signaling is lost during prostate cancer progression to castration resistance. PMID:26573794
These data provide a rationale for further evaluation of the combination of Wee1 and Chk1/2 inhibitors in malignant melanoma. PMID:26054341
Variants at the CHEK2 locus are associated with risk of invasive epithelial ovarian cancer. [meta-analysis] PMID:26424751
CHEK2 H371Y mutation carriers are more likely to respond to neoadjuvant chemotherapy than are non-carriers PMID:25884806

Hide All

Subcellular Location

[Isoform 2]: Nucleus. Note=Isoform 10 is present throughout the cell.; [Isoform 4]: Nucleus.; [Isoform 7]: Nucleus.; [Isoform 9]: Nucleus.; [Isoform 12]: Nucleus.; Nucleus, PML body. Nucleus, nucleoplasm. Note=Recruited into PML bodies together with TP53.

Protein Families

Protein kinase superfamily, CAMK Ser/Thr protein kinase family, CHK2 subfamily

Tissue Specificity

High expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.

Database Links

HGNC: 16627

UNIGENE: Hs.291363

KEGG: hsa:11200

OMIM: 114480

Promotions